Agdia competitors

Ron Squarer serves as Chairman and Executive Advisor at ADC Therapeutics SA (NYSE: ADCT) and directly supported the May 2020 company IPO. Mr. Squarer served as Chief Executive Officer and a member of the Array Biopharma Board of Directors from April 2012 through August 2019 when Pfizer Inc. acquired the company for $11.8 billion following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, the company’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is recognized for having invented Vitrakvi®/larotrectinib/TRK, Koselugo®/selumetinib/MEK, Tukysa®/tucatinib/HER2, ipatasertib/AKT, selpercatinib/RET, and MRTX849/KRAS-G12C among other molecules. Mr. Squarer has extensive commercial, development, research prioritization, and executive leadership expertise from a career spanning more than two decades in the biopharmaceutical industry. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. In his last role there, as Senior Vice President and Chief Commercial Officer, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer, Inc. (including in Oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe and currently serves as a member of the Board of Directors of Deciphera Inc. (NASDAQ: DCPH) and Travere Therapeutics Inc. (NASDAQ: TVTX) Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.

Experienced Board Member and leader with a demonstrated history of working in the biotechnology industry. Skilled in Business Planning, Biotechnology, Team Leadership, Management, and Risk Financing. Strong business development professional with a MBA focused in Accounting from University of Wisconsin-Madison.